Zaprinast
-
Zaprinast
structure -
-
CAS No:
37762-06-4
-
Formula:
C13H13N5O2
-
Chemical Name:
Zaprinast
-
Synonyms:
7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one,3,6-dihydro-5-(2-propoxyphenyl)-;7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one,1,4-dihydro-5-(2-propoxyphenyl)-;3,6-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one;8-Aza-2-(2-propoxyphenyl)-6-purinone;2-(o-Propoxyphenyl)-8-azapurin-6-one;M&B 22,948;M and B 22948;Zaprinast;2-(2-Propoxyphenyl)-8-aza-6-purinone;5-(2-Propoxyphenyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one;M&B 22948;55122-20-8;68560-67-8
- Categories:
-
CAS No:
Description
Zaprinast (M&B 22948) is an inhibitor of cGMP-selective Phosphodiesterases(PDEs)[1]. Zaprinast is a G protein-coupled receptor (GPR) 35 agonist which activates rat GPR35 strongly and activates human GPR35 moderately[2]. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects[3].
5-(2-propoxyphenyl)-2,3-dihydrotriazolo[4,5-d]pyrimidin-7-one is a member of triazolopyrimidines.
Characteristics
87.4
0.17
white solid
1.484g/cm3
241 °C (decomp)
406.3±47.0 °C at 760 mmHg
199.5±29.3 °C
1.719
soluble to 100 mM in DMSO;45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.11 mg/mL
Store at RT
159.2 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
Safety Information
NONH for all modes of transport
3
36/37/38
26-36
XZ6157358
Xi
P261-P305 + P351 + P338
H315-H319-H335
|Warning|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Information
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)
2-(2-propoxyphenyl)-8-azapurin-6-one
Zaprinast Use and Manufacturing
A selective inhibitor of cyclic-GMP phosphodiesterase (PDE V, calmodulin insensitive). Since cGMP mediates the vasorelaxant action of nitric oxide, as well as the natriuretic and diuretic effect of atrial natriuretic factor (ANF) through the activation of PKG (cGMP dependent protein kinase), such inhibitors may display vasodilating, relaxant, and diuretic effects.These compounds may prove useful in treating hypertension and congestive heart failure.
Computed Properties
Molecular Weight:271.27
XLogP3:1.6
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:4
Exact Mass:271.10692467
Monoisotopic Mass:271.10692467
Topological Polar Surface Area:92.3
Heavy Atom Count:20
Complexity:400
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of Zaprinast
-
US
6 YRS
Business licensed Certified factoryManufactory Supplier of Coenzymes,Inhibito,Enzymes,Zymogens,Substrates
Learn More Other Chemicals
-
Pseudopurpurin
476-41-5
-
Glycidic acid
503-11-7
-
Olopatadine
113806-05-6
-
(±)-Carbinoxamine Formula
486-16-8
-
(±)-Promethazine Formula
60-87-7
-
(+)-Chlorpheniramine Formula
25523-97-1
-
Dipicrylamine Structure
131-73-7
-
Thenalidine Structure
86-12-4
-
What is Thiazinamium methyl sulfate
58-34-4
-
What is Bromodiphenhydramine
118-23-0